Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

RF pain device developer Relievant completes $30mm Series D financing

Executive Summary

New Enterprise Associates has led a $30mm Series D round for Relievant Medsystems Inc. (radiofrequency nerve ablation devices). Returning shareholders Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures, and Onset Ventures also joined. The funding will support Relievant’s recently initiated surgical multi-center assessment of RF ablation for the treatment of vertebrogenic back pain (SMART) trial, which will evaluate the Intracept system in chronic axial low back pain. The minimally invasive probe delivers radiofrequency ablation to prevent pain signals from being transmitted by the basivertebral nerve.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Radiofrequency Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies